An Open-label, Multiple-dosing, Two-arms, One-sequence Study to Evaluate the Safety and Pharmacokinetics After Co-administration of UIC201601 and UIC201602 in Healthy Male Volunteers
Latest Information Update: 20 Jan 2022
At a glance
- Drugs UI 018 (Primary)
- Indications Hyperlipidaemia; Vascular disorders
- Focus Pharmacokinetics
- Sponsors Korea United Pharm Inc
- 20 Jan 2022 New trial record